CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed
Drug / intervention
lauromacrogoldrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00348764
NCT00348764Phase 3Completed
CompareCT.gov

Treatment of Greater Saphenous Vein (GSV) Insufficiency Using Echo-Guided Sclerotherapy With Lauromacrogol 400 Foam -Comparative Study of 3% Versus 1% Concentration.

University Hospital, Grenoble·interventional·Posted Jul 6, 2006·Updated Jul 6, 2006

In Brief

A Phase 3 clinical trial evaluating lauromacrogol for Venous Insufficiency and Saphenous Vein. Completed, across 1 site.

Detailed Summary

To evaluate the efficacy and the tolerance of echoguided sclerotherapy using Lauromacrogol 400 foam for the treatment of Great Saphenous Vein (GSV) insufficiency. A comparative study of 3% versus 1% Lauromacrogol 400 foam.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsVenous Insufficiency, Saphenous Vein
CountriesFrance
Collaborators--

Timeline

Phase 3CompletedFinished
200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJul 6, 2006
Enrollment StartMar 1, 2004
Study CompletionDec 1, 2006
TodayJul 2, 2026
Posted 20.0 years ago

Interventions

lauromacrogoldrug